AMKbiotech is an innovative service laboratory proving highplex tissue imaging solutions for biomarker identification and target efficacy validation.
About the solution
AMKbiotech combines the development of a novel tissue processing and imaging approach with AI-based analytical tools to generate 200 times more data from a single tissue section, while saving 80% of the resources needed for such analysis with classical histology approaches, in a 2 times faster execution period.
AgenT, founded in 2018, is on a mission to defeat Alzheimer’s by targeting the silent phase. Leveraging a groundbreaking multi-omics approach combined with A.I., they have identified new blood biomarkers deregulated from the earliest stages of the disease. Using this proprietary database, they have developed two blood tests, B-HEALED™ and B-AHEAD™, for early and precise detection during the pre-dementia stages, unlocking the future of precision medicine. Their innovation is crucial in the era of emerging treatments like Leqembi, enabling detection and treatment of Alzheimer’s before cognitive decline manifests.
By embracing precision medicine and expanding the biomarker toolkit, AgenT is positioning themselves for the next leap in Alzheimer’s treatment, ensuring patients receive the right therapy at the right time.
About the solution
Traditional Alzheimer’s tests detect brain amyloid levels—a risk factor, not a definitive diagnostic marker, leading to up to 25% false positives among mild cognitive impairment (MCI) patients. AgenT’s B-HEALED test dramatically reduces this false positive rate by two-thirds with its non-invasive, cost-effective, and scalable blood test, offering a breakthrough in Alzheimer’s diagnostics.
By accurately identifying MCI patients who can benefit from early intervention with disease-modifying treatments, their test ensures timely and precise therapy to slow Alzheimer’s progression effectively, without exposing non-Alzheimer’s patients to unnecessary drug side effects.
Cilcare is a biotech dedicated to harnessing auditory sciences to reshape the future of care via early diagnosis and targeted treatment. They believe hearing acts as a valuable indicator of our health and must be monitored and preserved accordingly. As awareness of the link between hearing and chronic health conditions grows, auditory sciences are paving the way for the early detection of chronic neurocognitive, inflammatory, and age-related diseases.
Founded in 2014 by three women with extensive backgrounds in the pharmaceutical industry, Cilcare initially aimed to address the significant unmet medical needs in ear diseases. Its approach focuses on translational research, supported by a cutting-edge R&D platform with robust pharmacological models. Partnering with CBSET, a translational institute linked to the MIT in 2017, Cilcare accelerated its mission, to drive transformative breakthroughs. Developing its own assets coupled with a unique AI-driven approach, Cilcare focuses on cochlear synaptopathy treatment and associated neuro-inflammatory disorders.
About the solution
Cilcare stands out with a revolutionary strategy that merges drug development with state-of-the-art AI-driven approach, specifically tailored for auditory data analysis. Cilcare’s lead compound, CIL001, is ready to enter phase IIA in the treatment of cochlear synaptopathy, a hot topic in the scientific community, and affecting 15% of the population. Addressing an underexplored therapeutic domain, with a unique pharmacological pathway, position Cilcare and its lead compound at the forefront of innovation in the field of auditory sciences.
Inovotion is a breakthrough in vivo platform without animal experimentation-3Rs with multiple value creation applications in Drug Discovery and Personalize Medicine.
Inovotion’s Drug Discovery solution, for anticancer drugs including Immuno-Oncology, deliver faster results, higher sensitivity, strong reliability, and very large cost savings. By eliminating low-value molecules, Inovotion accelerates the drug discovery process and significantly reduces its costs and the animal use. Inovotion has carried out over 650 in vivo studies for over 130 customers in Pharma and Biotech in Europe, USA, and Asia.
Inovotion develops new applications for Personalized Medicine, based on a unique assay to grow tumor avatars derived from patients’ Organoids, Biopsies or Circulating Tumor Cells (CTCs). Inovotion has so far self-financed the development of its multi-function platform though a successful CRO business (over 45% growth in 2023). Inovotion is now seeking a powerful partner to accelerate its development and disseminate throughout the Biopharma industry in USA and Europe.
About the solution
Inovotion’s Drug Discovery solution is tailored for anticancer drugs, including those in Immuno-Oncology. It provides quicker outcomes, enhanced sensitivity, exceptional reliability, and substantial cost reductions compared to traditional models. By weeding out molecules of low potential, Inovotion expedites the drug discovery journey, drastically cutting down on expenses and the need for animal testing.
Their next generation of in vivo efficacy and toxicity tests: #EFFICACY of oncology or immuno-oncology drugs #EARLY TOXICITY assays #TARGET VALIDATION in oncology #MULTI-CANCER SCREENING to (re)position #MECHANISM OF ACTION (angiogenesis, fibrosis, immune cell infiltration, transciptomic, PK,…) INOVOTION has also developed news assay dedicated to the evaluation of biomaterial.
OSE Immunotherapeutics is an integrated Clinical Stage biotech company mastering complex biology with regards to T-cells and myeloid cells, focused on developing first-in-class assets targeting immuno-oncology, Autoimmune and inflammatory diseases.
About the solution
OSE Immunotherapeutics has a dynamic partnership business model based on innovative products that generates non-dilutive revenues and finances R&D programs. These products have real blockbuster potential and give to OSE-Immunotherapeutics, an ability to conclude global agreements at different stages of their development with major pharmaceuticals players. We are interested to discuss potential collaborations. OSE-Immunotherapeutics actively seeks international partners for out-Licencing of compounds at all stages of clinical development of drug products.
Founded with the goal of revolutionizing precision medicine, Surge is an innovative company specializing in in-depth understanding of the immune system using AI. Thanks to significant technological advancements and a team of top-notch researchers coming from the US and from France, Surge is committed to creating innovative solutions to pave the way for personalized medicine of tomorrow. With the launch of its first product, PreCyte®, for predicting the risk of postoperative complications, and its premier laboratory, SurgeLab™, for acquiring individualized immune signatures, the company aims to become a leader in precision immune analysis.
About the solution
SurgeCare develops two main products : – SurgeLab™, a lab platform focused on acquiring immune signatures, and – PreCyte®, a range of medical devices for precision medicine.
Founded in 2021 with innovative technology for identifying predictive immune biomarkers, Surge, from 2021 to 2023, developed a first prototype to anticipate the risk of post-operative infections in patients undergoing major digestive surgery. A clinical study conducted from 2022 to 2023 revealed that their prototype outperforms existing methods by more than three times in terms of predictive capability. In 2024, this prototype enters its final phase of industrialization, with deployment planned as a pilot in the fourth quarter of 2024.
Meanwhile, in response to the growing interest of their partners, they have initiated the opening of their SurgeLab platform, which offers comprehensive immune screening, including ex-vivo blood stimulation, collection of biological parameters via a specialized panel, and data analysis through machine learning, reinforcing their commitment to innovation in precision medicine.
Neuron Experts is a private CRO, created in 2008, specialized in cultures of neurons mimicking neurodegenerative diseases. It is located in Marseille, France, where it has 250 m² of independent laboratory. 80% of its turnover is exported.
About the solution
Neuron Experts has developed its own tests based human and rat invitro models reproducing neurodegenerative diseases such as AD, PD, HD, ALS, MS diseases. These models allow to test efficacy of compounds from pharmaceutical and start-up as well as understanding their mode of action in theses pathologies
PK MED is a French innovative biotech company, privately owned and established in 2019 with the support of Truffle Capital, a prominent European Venture Capital firm specializing in Life sciences.
PK MED specializes in the innovative development of custom-designed, injectable, and biodegradable micro-implants. Their expertise spans across critical healthcare domains, focusing on local drug delivery systems for rheumatology (PKM-01) and enhancing cell-homing techniques to improve bone marrow transplantation outcomes (PKM-02).
About the solution
Lead product candidate PKM-01 is developed to treat gout, an excruciating and increasingly prevalent form of arthritis. Today, approved products take time to partially alleviate pain and come with real safety risks. PKM-01 is a drug combination product (sustained release formulation of the anti-inflammatory drug, colchicine, and an anesthetic) to be injected in the effected joint. PKM-01 is designed to be a new treatment paradigm in gout flares – a safe and very effective pain killer providing relief within minutes.
Nicox is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Their lead program in the ophthalmic pipeline, NCX 470, is currently in Phase 3 clinical development targeting glaucoma. Their ophthalmic pipeline also includes a candidate under preclinical evaluation for development in retinal conditions, NCX 1728, and a clinical-stage product candidate for dry eye disease licensed exclusively to a partner for the Chinese market, NCX 4251.
They have two products commercialized in the U.S.: VYZULTA® (latanoprostene bunod ophthalmic solution) 0.024% for open-angle glaucoma and ZERVIATE® (cetirizine ophthalmic solution) 0.24% for ocular allergic conjunctivitis. These products are being rolled out in territories outside of the U.S. through partnerships.
About the solution
NCX 470 is a novel nitric oxide (NO)-donating bimatoprost eye drop targeting glaucoma that leverages the potent intraocular pressure (IOP)-lowering effects of NO and prostaglandin analogs (PGAs). NCX 470 incorporates Nicox’s proprietary NO-donating research platform and bimatoprost in a single molecule. The first of two Phase 3 trials for NCX 470, Mont Blanc, met the efficacy requirements for approval in the U.S. The similarly designed and ongoing second Phase 3 trial, Denali, conducted at clinical sites in the U.S. and China is ongoing with topline results are expected in H2 2025.
Apmonia Therapeutics is a biotechnology company dedicated to developing therapeutic strategies towards cancer. They are developing a first-in-class pipeline of next-generation peptide-based therapies targeting the tumor microenvironment to improve the lives of patients with cancer.
Using molecular modeling (i.e., ligand:protein and protein:protein docking simulations, as well as molecular dynamics simulations) and their vast knowledge of matrix biology and oncology, they are developing a portfolio of proprietary first-in-class peptide-based therapies targeting the tumour extracellular matrix (ECM) molecules. After years of research on cancer-stroma interactions, they identified several proteins which are overexpressed in different types of solid tumours, converting them into potential targets for anticancer treatments. By producing peptides that selectively target ECM components, they can regulate the interplay between cancer and stromal cells within the TME, disrupting tumoural activity.
About the solution
Their lead program, AP-01 (or TAX2), is a peptide-based technology targeting tumor-overexpressed thrombospondin-1 (TSP-1) to prevent CD47 receptor activation. AP-01 acts as a modulator of the tumor-tolerant microenvironment, reprogramming highly vascularized tumors into poorly angiogenic ones while concomitantly activating the tumor-inhibiting immune system. Thanks to its unique mode of action, AP-01 does not recapitulate the hematologic toxicities related to CD47 blockade, hence realizing the full potential of targeting this axis for cancer therapy.
A large body of in vivo efficacy data supports the proof-of-concept for AP-01 use as an anti-cancer therapy. TAX2 activates the adaptive (tumor-specific) immune response, as demonstrated by activation of T-cells, production of interferon gamma, and significant tumor reduction. The T cell stimulatory activities of AP-01 also position it as an excellent candidate for combination therapies in the context of a broad immune-oncology approach.
Their current focus for clinical development is ovarian cancer, an orphan indication. They plan to target other indications including glioblastoma, colorectal cancer, and pancreatic cancer.
